Sotio

Last updated
SOTIO
Industry Biotechnology, Pharmaceutical
Founded2010
FounderPetr Kellner
Headquarters
Prague
,
Czech Republic
Key people
Radek Spisek, Ph.D., CEO
Revenue176,068,000 Czech koruna (2021)  OOjs UI icon edit-ltr-progressive.svg
−319,386,000 Czech koruna (2021)  OOjs UI icon edit-ltr-progressive.svg
−344,344,000 Czech koruna (2021)  OOjs UI icon edit-ltr-progressive.svg
Total assets 6,689,850,000 Czech koruna (2021)  OOjs UI icon edit-ltr-progressive.svg
Number of employees
200
Website https://www.sotio.com/

SOTIO Biotech [1] is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, North America, and Asia. [2] The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), proprietary technology designed to improve on the efficacy of CAR T therapies and a platform to streamline and enhance personalized cell therapies. [3]

Contents

Founding

The company was founded in 2010 and in 2012 became part of PPF Group, owned by Petr Kellner. [4] The CEO of the company is Radek Špíšek, who has been with the company since its beginning, initially functioning as Chief Scientific Officer. [5]

Operations

SOTIO conducts global operations in Europe, the USA, and China. In January 2020, the company announced the founding of its subsidiary SOTIO Biotech AG in Basel, Switzerland. [6] SOTIO also operates laboratory complexes Prague, Czech Republic and Beijing, China where it produces treatments for people suffering from oncological diseases. [7]

Pipeline

SOTIO is currently testing multiple oncology products at different stages of clinical development. [8]

IL-15 Superagonist

Immune cytokine IL-15 is an immuno-oncology target that mobilizes cytotoxic T cells and natural killer (NK) cells. Stimulating IL-15 receptors on these cells represents a potent and complementary mechanism to existing cancer treatments. [9]

SOTIO is developing an IL-15 superagonist, SO-C101, which is designed to have significant advantages over other IL-2 and IL-15 based therapies that are currently in development. SO-C101 is fused to the IL-15 alpha chain receptor, which confers specific binding to cytotoxic T cell and NK cells, which may provide superior efficacy and safety profile. Fusion to the IL-15 alpha chain receptor also optimizes half-life, which may improve efficacy by limiting T cell exhaustion. [10]

SOTIO is currently conducting an ongoing Phase 1/1b dose finding study at leading clinical centers in the U.S. and EU to examine SO-C101 as monotherapy and in combination with pembrolizumab in patients with relapsed/refractory advanced/metastatic solid tumors. Interim data demonstrate that SO-C101 has been well tolerated to date, with no dose limiting toxicities observed. [11]

BOXR

SOTIO's BOXR cell therapy platform is designed to improve functionality of engineered T cells by discovering novel “bolt-on” transgenes that can be co-expressed with tumor-targeting receptors to overcome resistance and improve the function of T cells in the solid tumor microenvironment. [12]

Lead candidate BOXR1030 uniquely combines the BOXR-discovered GOT2 transgene, a critical enzyme involved in cellular metabolism, with CAR T technology. BOXR1030 is designed to improve CAR T therapy function in the microenvironment by enhancing T cell fitness in the solid tumor microenvironment. Tumor infiltrating lymphocytes isolated from the tumors of treated animals revealed that BOXR1030 cells were more resistant to dysfunction and had fewer markers of exhaustion as compared to the control CAR T cells. [13]

Antibody Drug Conjugates

SOTIO, in collaboration with its partner NBE Therapeutics, is developing oncology candidates based on its platform of potent and highly stable ADCs with an unprecedented therapeutic window. Preclinical data show that these ADCs have a strong efficacy in direct tumor cell killing and a good tolerability profile, but also induce specific antitumor immunity, thereby providing a dual approach to cancer protection. SOTIO currently has two antibody drug conjugate candidates in preclinical trials, SOT102 and SOT107. [14] [15]

Partners

SOTIO has its own scientific research and development and also collaborates with other partners. In recent years, SOTIO and PPF have focused on investing in a number of biotechnology companies developing innovative anticancer treatments in Europe and the US. Such as the Swiss NBE-Therapeutics on the development of novel antibody-drug conjugate products (ADC), with its affiliate Cytune Pharma on developing novel IL-15-based immunotherapies for the treatment of cancer. [16] [17] [18] [19]

In August 2018, SOTIO acquired Cytune Pharma [20] and announced the continued development of the company's lead program SO-C101 (RLI-15) which is a human fusion protein of IL-15 and the high-affinity binding domain of IL-15Ra. It is a novel immunotherapeutic approach to cancer treatment with potential applications in a variety of oncology indications. The first clinical trial for the program was launched in summer 2019. [21] [22] [23] [24]

Investments

At the end of 2020, PPF sold its stake in NBE-Therapeutics, a company developing innovative ADC products for the treatment of solid tumours, to the leading global pharmaceutical company Boehringer Ingelheim. This deal, the largest of its kind to be witnessed in Europe in ten years, showed the value of the ADCs that SOTIO maintains in its portfolio and that it continues to develop. These products could reach their first patients in 2022 in the first phase of clinical trials.

SOTIO is also managing PPF's investments in biotechnology companies Autolus Therapeutics and Cellestia Biotech. [25]

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

<span class="mw-page-title-main">Daiichi Sankyo</span> Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.

<span class="mw-page-title-main">Monoclonal antibody therapy</span> Form of immunotherapy

Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines. They can be used to render their target ineffective, to induce a specific cell signal, to cause the immune system to attack specific cells, or to bring a drug to a specific cell type.

Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).

<span class="mw-page-title-main">Antibody–drug conjugate</span> Class of biopharmaceutical drugs

Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs.

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

<span class="mw-page-title-main">Sutro Biopharma</span> Biotechnology company based in South San Francisco, California

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.

ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.

Kite Pharma is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

<span class="mw-page-title-main">Immune checkpoint</span> Regulators of the immune system

Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately. However, some cancers can protect themselves from attack by stimulating immune checkpoint targets.

<span class="mw-page-title-main">Emactuzumab</span> Monoclonal antibody

Emactuzumab (RG-7155) is a humanized monoclonal antibody directed against colony stimulating factor 1 receptor (CSF-1R) expressed on macrophages and has demonstrated a profound antitumor effect through interference with the CSF-1/CSF-1R axis, along with a manageable safety profile in patients with diffuse-type tenosynovial giant cell tumors (d-TGCT).

<span class="mw-page-title-main">Halozyme</span> Biotechnology company

Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.

<span class="mw-page-title-main">Loncastuximab tesirine</span> Medication

Loncastuximab tesirine, sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma. It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19.

Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics.

<span class="mw-page-title-main">Lurbinectedin</span> Chemical compound

Lurbinectedin, sold under the brand name Zepzelca, is a medication used for the treatment of small cell lung cancer.

Globo H (globohexaosylceramide) is a globo-series glycosphingolipid antigen that is present on the outer membrane of some cancer cells. Globo H is not expressed in normal tissue cells, but is expressed in a number of types of cancers, including cancers of the breast, prostate, and pancreas. Globo H's exclusivity for cancer cells makes it a target of interest for cancer therapies.

<span class="mw-page-title-main">SCTbio</span>

SCTbio is global contract development and manufacturing organization (CDMO) providing cGMP services of Advanced Therapy Medicinal Products (ATMPs). It operates in Europe and North America. The company has strong expertise in the development of autologous cell-based products, cell banking and all needle-to-needle GMP operations, including a validated apheresis collection sites network, product manufacturing, QC, GMP storage, QA/QP release, and worldwide drug products supply for clinical and commercial scale.

References

  1. ↑ SOTIO, Biotech. "The Company". Sotio. Retrieved 2022-03-15.
  2. ↑ "An In-Depth Look at Innovation on Cancer Research Day". BioSpace. Retrieved 2022-03-15.
  3. ↑ "SOTIO's Quest To Build A Global Biopharma". bioprocessonline.com. Retrieved 2022-03-15.
  4. ↑ "SOTIO Arms Dendritic Cells for Immunotherapy Against Cancer". WuXi XPress. Retrieved 2022-03-15.
  5. ↑ "Leadership". Sotio. Retrieved 2022-03-15.
  6. ↑ "Czech PPF Group biotech firms begin trials to extend lives of cancer patients". Radio Prague International. 2019-07-11. Retrieved 2022-03-15.
  7. ↑ "Carbios tackles marine littering". european-biotechnology.com. 13 December 2018. Retrieved 2022-03-15.
  8. ↑ "SOTIO Biotech Pipeline". Sotio. Retrieved 2022-03-15.
  9. ↑ Perera, Pin-Yu; Lichy, Jack H.; Waldmann, Thomas A.; Perera, Liyanage P. (2012). "The role of Interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use". Microbes and Infection / Institut Pasteur. 14 (3): 247–261. doi:10.1016/j.micinf.2011.10.006. ISSN   1286-4579. PMC   3270128 . PMID   22064066.
  10. ↑ "Developing IL-15 superagonists for cancer therapy". Drug Target Review. Retrieved 2022-03-15.
  11. ↑ "Genetically Engineering An IL-15 Superagonist". bioprocessonline.com. Retrieved 2022-03-15.
  12. ↑ "Sotio licences Unum Therapeutics' CAR-T cell portfolio". european-biotechnology.com. 31 August 2020. Retrieved 2022-03-15.
  13. ↑ "Personalized cell therapies offer hope for some of the toughest cancers". ScienceBoard.net. Retrieved 2022-03-15.
  14. ↑ "SOTIO, NBE Therapeutics Collaborate". Cancer Research from Technology Networks. Retrieved 2022-03-15.
  15. ↑ "New partner and investor for NBE Therapeutics". startupticker.ch. Retrieved 2022-03-15.
  16. ↑ "SOTIO prolongs collaboration with NBE-Therapeutics to develop antibody-drug conjugates". Swiss Biotech. Retrieved 2022-03-15.
  17. ↑ "As simple as ADC". Drug Discovery News. Retrieved 2022-03-15.
  18. ↑ "PPF's Biotech Divisions Report Advances In Cancer Research". Prague Business Journal. 2019-07-11. Retrieved 2022-03-15.
  19. ↑ "LDC and SOTIO License and Collaboration Agreement". old.firstwordpharma.com. Retrieved 2022-03-15.
  20. ↑ "SOTIO completes acquisition of Cytune Pharma". thepharmaletter.com. Retrieved 2022-03-15.
  21. ↑ "SOTIO expands collaboration with NBE Therapeutics". startupticker.ch. Retrieved 2022-03-15.
  22. ↑ "Czech billionaire Kellner's PPF Group expands in biotech with Autolus stake". Reuters. 2019-09-16. Retrieved 2022-03-15.
  23. ↑ "SOTIO, biotech major acquires Cytune Pharma". Elets eHealth. September 2018. Retrieved 2022-03-15.
  24. ↑ "PPF Group & Sotio complete acquisition of Cytune". European Pharmaceutical Manufacturer. 2018-08-31. Retrieved 2022-03-15.
  25. ↑ "Sotio". PPF Group. Retrieved 2022-03-15.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.